MedTrace Logo

Use of Nafamostat Mesilate for Anticoagulation in Patients With ECMO

NCT06276010 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2025-09-25

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effectiveness and safety of nafamostat mesilate compared with unfractionated heparin for anticoagulation in patients with ECMO after cardiac surgery.

Conditions

  • Extracorporeal Membrane Oxygenation Complication

Interventions

DRUG

nafamostat mesilate

Use nafamostat mesilate as an anticoagulant

DRUG

unfractionated heparin group

Use unfractionated heparin as an anticoagulant

Sponsors & Collaborators

  • Xiaotong Hou

    lead OTHER

Principal Investigators

  • Zhongtao Du, MD · Beijing Anzhen Hospital

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-01
Primary Completion
2026-11-01
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06276010 on ClinicalTrials.gov